GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit, also known as SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit, is faster, easier, more scalable and automatable alternative to the traditional neutralizing antibody tests, such as virus neutralization test (VNT), pseudo-virus neutralization test (pVNT) and plaque reduction neutralization test (PRNT). The kit has the capability of measuring functional neutralizing antibodies (NAbs) within an hour instead of the days required by the traditional tests. cPass Neutralization Antibody detection kit does not require live biological materials or strict biosafety containment for testing (i.e. BSL3 containment). All aspects of the quality management system are certified to ISO 13485. GenScript has acquired CE mark (Europe) and HSA provisional approval (Singapore) and has been issued Emergency Use Authorization (EUA) by U.S. FDA. CPT code for the cPass kit is 86409.
cPass Neutralization Antibody Detection kit detects circulating neutralizing antibodies against SARS-CoV-2 that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein with the ACE2 cell surface receptor. This kit would be instrumental in vaccine and therapeutic development as it is suitable for all antibody isotypes and can be used to determine a neutralizing antibody in animal models without modification. The kit will also help in current COVID-19 investigations of sero-prevalence, assessment of herd immunity, longevity of protective immunity, efficacy of different vaccine candidates as well as tracking infection in animals.
- Global patent protection for the kit will be firmly implemented.
- 96 well ELISA format test with ACE2 protein attached to the plate and HRP labeled RBD is used for detection.
- Can be used with serum and plasma samples.
- The kit comes with positive and negative controls.
- 4 wells are typically used for the controls, so 92 wells can be used for samples.